Last reviewed · How we verify
VDPHL01
VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme.
VDPHL01 is a small molecule that targets the H3 histone deacetylase (HDAC) enzyme. Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | VDPHL01 |
|---|---|
| Sponsor | Veradermics, Inc. |
| Drug class | HDAC inhibitor |
| Target | H3 histone deacetylase (HDAC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting H3 HDAC, VDPHL01 aims to modulate gene expression and potentially treat various diseases. This mechanism is being explored in phase 3 clinical trials, but more research is needed to fully understand its effects.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Safety and Efficacy of VDPHL01 in Males With AGA (PHASE3)
- Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) (PHASE3)
- Efficacy and Safety of VDPHL01 in Males With AGA (PHASE2, PHASE3)
- Safety and Efficacy of VDPHL01 in Males and Females With AGA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VDPHL01 CI brief — competitive landscape report
- VDPHL01 updates RSS · CI watch RSS
- Veradermics, Inc. portfolio CI